NewsBenzingaHC Wainwright & Co. reitera su recomendación de compra sobre Aclaris Therapeutics y mantiene el precio objetivo en 16 dólares. HC Wainwright & Co. reitera su recomendación de compra sobre Aclaris Therapeutics y mantiene el precio objetivo en 16 dólares. Benzinga 2026.10.28 10:59 (GMT+0) Open on Benzinga Other news Airbnb Co-Founder Joe Gebbia Says He Modernized Federal Retirement System In 6 Months for $1.5 Million After Contractors Spent $100 Million NVIDIA's Jensen Huang Crisis Threatens to Rewrite the Rules of the AI Boom Mondelez's Multi-Million Portfolio Shift: Unloads French Bakery and Cereal Bars Business Ur-Energy Begins Fieldwork For Baseline Studies At Its Lost Solider Project; Will Take Construction Decision For Potential Third Mine After Technical Report Alibaba Is Facing a Perfect Storm, and Q2 Earnings Won’t Be a Magical Fix for BABA Stock CME Stock: Is Wall Street Bullish or Bearish?
Airbnb Co-Founder Joe Gebbia Says He Modernized Federal Retirement System In 6 Months for $1.5 Million After Contractors Spent $100 Million
Ur-Energy Begins Fieldwork For Baseline Studies At Its Lost Solider Project; Will Take Construction Decision For Potential Third Mine After Technical Report